AR069393A1 - Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo - Google Patents
Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismoInfo
- Publication number
- AR069393A1 AR069393A1 ARP080105061A ARP080105061A AR069393A1 AR 069393 A1 AR069393 A1 AR 069393A1 AR P080105061 A ARP080105061 A AR P080105061A AR P080105061 A ARP080105061 A AR P080105061A AR 069393 A1 AR069393 A1 AR 069393A1
- Authority
- AR
- Argentina
- Prior art keywords
- ron
- antibodies
- stimulating protein
- macrofago
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anticuerpos o fragmentos del mismo, incluyendo anticuerpos humanos, específicos para el Receptor para la Proteína Estimulante del Macrofago (MSP-R o RON), que inhiben la activacion del RON. También se proporciona un método para inhibir el RON, en especial el uso de anticuerpos del RON para tratar enfermedades como el cáncer así como composiciones farmacéuticas que comprende tales anticuerpos además ácidos nucleicos que codifican anticuerpos, vectores que comprenden y células huésped.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98955807P | 2007-11-21 | 2007-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069393A1 true AR069393A1 (es) | 2010-01-20 |
Family
ID=40364492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105061A AR069393A1 (es) | 2007-11-21 | 2008-11-20 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo |
Country Status (20)
Country | Link |
---|---|
US (2) | US7947811B2 (es) |
EP (1) | EP2222703A2 (es) |
JP (1) | JP5324593B2 (es) |
KR (1) | KR101227338B1 (es) |
CN (1) | CN101868478B (es) |
AR (1) | AR069393A1 (es) |
AU (1) | AU2008330089B2 (es) |
BR (1) | BRPI0820218A2 (es) |
CA (1) | CA2706583A1 (es) |
CL (1) | CL2008003449A1 (es) |
EA (1) | EA018717B1 (es) |
IL (1) | IL204743A (es) |
MX (1) | MX2010005651A (es) |
NZ (1) | NZ584271A (es) |
PA (1) | PA8804901A1 (es) |
PE (1) | PE20091713A1 (es) |
TW (1) | TWI417106B (es) |
UA (1) | UA99633C2 (es) |
UY (1) | UY31478A1 (es) |
WO (1) | WO2009070294A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
CN101977937A (zh) * | 2008-01-22 | 2011-02-16 | 拜奥根Idec马萨诸塞公司 | Ron抗体及其用途 |
EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
AR070317A1 (es) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
TWI480050B (zh) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗-mst1r抗體及其用途 |
AU2010343057B2 (en) * | 2009-12-29 | 2017-02-23 | Aptevo Research And Development Llc | Heterodimer binding proteins and uses thereof |
US8603478B2 (en) | 2010-07-06 | 2013-12-10 | Aveo Pharmaceuticals, Inc. | Anti-RON antibodies |
US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
CN103702682A (zh) | 2011-04-21 | 2014-04-02 | 科罗拉多州立大学董事会法人团体 | 治疗视神经脊髓炎的组合物和方法 |
JP2015527869A (ja) | 2011-08-26 | 2015-09-24 | メリマック ファーマシューティカルズ インコーポレーティッド | タンデムFc二重特異性抗体 |
CN104168915A (zh) | 2011-11-14 | 2014-11-26 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
CN104822706A (zh) * | 2012-11-30 | 2015-08-05 | 弗·哈夫曼-拉罗切有限公司 | Ron组合物及其使用方法 |
CN104936987A (zh) * | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | 抗mcsp抗体 |
CA2902505A1 (en) | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
ES2750832T3 (es) * | 2014-07-29 | 2020-03-27 | Wellmarker Bio Co Ltd | Nuevo biomarcador para predecir la sensibilidad al agente dirigido contra egfr y uso del mismo |
KR101862719B1 (ko) * | 2014-09-03 | 2018-05-31 | 웰마커바이오 주식회사 | 단백질 키나제 억제제에 대한 감수성 예측용 바이오 마커 및 이의 용도 |
JP2020500834A (ja) * | 2016-08-26 | 2020-01-16 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | マクロファージ刺激タンパク質受容体(又はRON(Recepteur d′Origine Nantais))抗体及びその使用 |
WO2018052789A1 (en) | 2016-09-08 | 2018-03-22 | Pcm Targetech, Llc | Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy |
US20220372125A1 (en) * | 2019-10-02 | 2022-11-24 | Aslan Pharmaceuticals Pte. Ltd. | Antigen Specific Binding Domains and Antibody Molecules |
WO2022060906A1 (en) * | 2020-09-15 | 2022-03-24 | Duke University | Coronavirus antibodies and uses thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992014748A1 (en) | 1991-02-22 | 1992-09-03 | American Cyanamid Company | Identification of a novel human receptor tyrosine kinase gene |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
US5861301A (en) | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
DE122005000053I2 (de) | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
WO2001090192A2 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
EP1311291A4 (en) | 2000-08-09 | 2007-07-25 | Imclone Systems Inc | TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS |
SE518548C2 (sv) | 2001-04-11 | 2002-10-22 | Sca Hygiene Prod Ab | Absorberande alster med förbättrad diskretion |
US7235523B2 (en) | 2001-04-13 | 2007-06-26 | Children's Hospital Medical Center | Methods for the treatment of hepatic disorders |
JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
ES2347543T3 (es) | 2002-03-04 | 2010-11-02 | Imclone Llc | Anticuerpos humanos especificos para kdr y sus usos. |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US20040185506A1 (en) | 2003-03-21 | 2004-09-23 | Heavner George A. | Epitope mapping using nuclear magnetic resonance |
JP2007535895A (ja) | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−1受容体に対する完全ヒト抗体 |
EP1773881A4 (en) * | 2004-05-13 | 2008-08-06 | Imclone Systems Inc | Inhibition of macrophage-stimulating protein receptor (RON) |
-
2008
- 2008-11-20 AR ARP080105061A patent/AR069393A1/es not_active Application Discontinuation
- 2008-11-20 CL CL2008003449A patent/CL2008003449A1/es unknown
- 2008-11-20 UY UY31478A patent/UY31478A1/es not_active Application Discontinuation
- 2008-11-21 UA UAA201006208A patent/UA99633C2/ru unknown
- 2008-11-21 AU AU2008330089A patent/AU2008330089B2/en not_active Ceased
- 2008-11-21 JP JP2010534977A patent/JP5324593B2/ja not_active Expired - Fee Related
- 2008-11-21 NZ NZ584271A patent/NZ584271A/en not_active IP Right Cessation
- 2008-11-21 TW TW097145251A patent/TWI417106B/zh not_active IP Right Cessation
- 2008-11-21 EA EA201070636A patent/EA018717B1/ru not_active IP Right Cessation
- 2008-11-21 WO PCT/US2008/013130 patent/WO2009070294A2/en active Application Filing
- 2008-11-21 US US12/313,589 patent/US7947811B2/en not_active Expired - Fee Related
- 2008-11-21 PA PA20088804901A patent/PA8804901A1/es unknown
- 2008-11-21 MX MX2010005651A patent/MX2010005651A/es active IP Right Grant
- 2008-11-21 CA CA2706583A patent/CA2706583A1/en not_active Abandoned
- 2008-11-21 KR KR1020107011065A patent/KR101227338B1/ko not_active IP Right Cessation
- 2008-11-21 BR BRPI0820218-4A patent/BRPI0820218A2/pt not_active IP Right Cessation
- 2008-11-21 EP EP08854059A patent/EP2222703A2/en not_active Withdrawn
- 2008-11-21 CN CN2008801172313A patent/CN101868478B/zh not_active Expired - Fee Related
- 2008-11-24 PE PE2008001959A patent/PE20091713A1/es not_active Application Discontinuation
-
2010
- 2010-03-25 IL IL204743A patent/IL204743A/en not_active IP Right Cessation
- 2010-12-14 US US12/967,241 patent/US8133489B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2009070294A2 (en) | 2009-06-04 |
UY31478A1 (es) | 2009-07-17 |
WO2009070294A3 (en) | 2009-08-20 |
CA2706583A1 (en) | 2009-06-04 |
PA8804901A1 (es) | 2009-06-23 |
CN101868478B (zh) | 2013-11-13 |
US7947811B2 (en) | 2011-05-24 |
KR101227338B1 (ko) | 2013-01-28 |
US8133489B2 (en) | 2012-03-13 |
AU2008330089A1 (en) | 2009-06-04 |
US20110135631A1 (en) | 2011-06-09 |
AU2008330089B2 (en) | 2013-09-05 |
TWI417106B (zh) | 2013-12-01 |
CL2008003449A1 (es) | 2010-02-19 |
IL204743A0 (en) | 2010-11-30 |
IL204743A (en) | 2013-10-31 |
JP2011504176A (ja) | 2011-02-03 |
BRPI0820218A2 (pt) | 2015-06-23 |
EP2222703A2 (en) | 2010-09-01 |
EA201070636A1 (ru) | 2010-10-29 |
US20090136510A1 (en) | 2009-05-28 |
JP5324593B2 (ja) | 2013-10-23 |
UA99633C2 (ru) | 2012-09-10 |
NZ584271A (en) | 2012-05-25 |
KR20100074293A (ko) | 2010-07-01 |
TW200936161A (en) | 2009-09-01 |
EA018717B1 (ru) | 2013-10-30 |
CN101868478A (zh) | 2010-10-20 |
MX2010005651A (es) | 2010-06-11 |
PE20091713A1 (es) | 2009-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069393A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo | |
CL2008000348A1 (es) | Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis. | |
CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
WO2016187220A3 (en) | Anti-ror1 antibodies | |
MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
EA201170155A1 (ru) | Специфические антагонисты рецептора fgf-r4 | |
CL2008000670A1 (es) | Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras. | |
UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
BR112012024382A2 (pt) | agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunesças | |
BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
EP2285989A4 (en) | NEW TARGETS TO REGULATE ANGIOGENESIS | |
CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
EA201291044A1 (ru) | Слитый белок robo1-fc и его применение в лечении опухолей | |
CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. | |
BR112012009432A8 (pt) | Anticorpo anti-hsv e composição farmacêutica que o compreende | |
EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
MA32183B1 (fr) | Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |